1.	Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11 SEIN 09, NCT01553903
2.	Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11SEIN12, NCT01612871
3.	Adjuvant AI Combined With Zoladex Phase: Phase III Type: Treatment Status: Active Age: 18 and over (Premenopausal) Sponsor: Other Protocol IDs: CBCSG002, NCT01352091
4.	Study of Arimidex and Radiotherapy Sequencing Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: BR-RT-002, NCT01402193
5.	Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000730083, CALGB-A221102, NCCTG-N10C7, A221102, NCT01573442
6.	A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. Phase: Phase III Type: Treatment Status: Active Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: D699BC00001, NCT01602380
7.	DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: DETECT III, 2010-024238-46, NCT01619111
8.	Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With Poor Prognosis, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving 3 Years of Adjuvant Hormone Therapy Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: UNIRAD, 2012-003187-44, UC-0140/1208, NCT01805271
9.	Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LCCC 2010-535, NCT01484041
10.	A Trial of AZD4547 for Breast Cancer That is Oestrogen Receptor Positive and Has Got Worse Despite Having Anastrozole or Letrozole Phase: Phase II, Phase I Type: Treatment Status: Active Age: 25 and over Sponsor: Other Protocol IDs: C/23/2011, 2011-000454-32, NCT01791985
11.	Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 117513, NCT01466972
12.	A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO27775, NCT01491737
13.	PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 201301106, NCT01723774
14.	Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2013-00080, MC1139, N01CM00099, NCT01776008
15.	Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 212082BCA2004, NCT01814865
16.	MK2206 and Anastrozole, Letrozole, Exemestane, or Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02586, 201010701, CDR0000699394, WU-201010701, P30CA091842, N01CM00099, 8762, NCT01344031
17.	S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer Phase: No phase specified Type: Behavioral study Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000723653, S1105, U10CA037429, SWOG-S1105, NCT01515800
18.	Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy Phase: No phase specified Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 7841, NCI-2012-02004, P30CA015704, NCT01720602
19.	Genetic Predictors of Musculoskeletal Symptoms in Patients Receiving Anastrozole for Stage I-III Breast Cancer Phase: No phase specified Type: Biomarker/Laboratory analysis, Supportive care Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: E1Z11, NCI-2013-00426, U10CA037403, NCT01824836